Section 14 · Monograph
Bevacizumab
Reviewed Nov 2026FDA label
AvastinAnti-VEGF mAb
- Forms
- IV: 100mg/4mL, 400mg/16mL
- Dose
- Recurrent glioblastoma: 10mg/kg IV every 2 weeks
- MOA
- Neutralizes VEGF-A, ↓angiogenesis and vasogenic edema
Indications
- Recurrent glioblastoma (progressive disease after prior therapy)FDA-labeled
- Metastatic colorectal, non-small cell lung, renal cell, cervical and ovarian cancersFDA-labeled
Mechanism of Action
- Humanized monoclonal antibody against VEGF-A, reducing tumor angiogenesis and vascular permeability (also lowers vasogenic edema and steroid requirement)
Full Dosing
Adult / usual
- Recurrent glioblastoma: 10mg/kg IV every 2 weeks until progression or unacceptable toxicity
- First infusion over 90 minutes; subsequent infusions over 60 then 30 minutes if tolerated
- Hold at least 28 days before elective surgery and until surgical wounds heal
Contraindications
- None listed in current labeling
Drug Interactions
- Anticoagulants and NSAIDs may add to bleeding risk
- Sunitinib combination associated with microangiopathic hemolytic anemia
Adverse Effects
- Hypertension
- Proteinuria and nephrotic syndrome
- GI perforation and impaired wound healing
- Hemorrhage, including intracranial
- Arterial thromboembolic events
- Posterior reversible encephalopathy syndrome
- Infusion reactions
Monitoring Parameters
- Blood pressure at every visit
- Urinalysis for proteinuria
- Bleeding and neurologic change; wound healing
Pregnancy & Lactation
- Embryo-fetal toxicity; effective contraception during and for about 6 months after treatment
- Breastfeeding not recommended during and for about 6 months after treatment